Cost-effectiveness of managing HBV reactivation in patients with resolved HBV infection treated with anti-CD20 antibody for B-cell non-Hodgkin lymphoma

There is no universal recommendation for managing the reactivation of HBV in patients with resolved HBV infection treated with anti-CD20 monoclonal antibodies for B-cell non-Hodgkin lymphoma. This study compared the cost-effectiveness of two commonly used strategies: prophylactic anti-HBV nucleos(t)...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Misuzu, Kusumoto, Shigeru, Ishii, Itsuko, Iwata, Tadashi, Fujisawa, Takehiko, Sugiyama, Masaya, Hata, Akira, Mizokami, Masashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072369/
https://www.ncbi.nlm.nih.gov/pubmed/35513395
http://dx.doi.org/10.1038/s41598-022-10665-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072369/
https://www.ncbi.nlm.nih.gov/pubmed/35513395
http://dx.doi.org/10.1038/s41598-022-10665-3

Ejemplares similares